Definitive Healthcare Corp.
NASDAQ:DHMedical - Healthcare Information Services
+$0.01 today
- Market cap
- $143.60M
- Beta
- 1.33
- P/E (TTM)
- -0.5
- EPS (TTM)
- -$1.63
Volume 0.43M
Average 0.32M
DH Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Definitive Healthcare Corp.NASDAQ: DH
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $6.5M fell 30.1% year over year, behind the -10.4% change in trailing-twelve-month research & development. Sequentially, it fell 34.7% from the prior quarter. Over 3 fiscal years it compounded at -0.1% a year.
Context
- Research & development amounted to 14.4% of revenue in FY2025, unchanged from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -30.1% toward the trailing-twelve-month pace of -10.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 34.78M USD
- Year-over-year change
- -4.8%
- 4-year CAGR
- +17.0%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 34.78M | -4.8% |
| FY2024 | 2024-12-31 | 36.52M | -14.0% |
| FY2023 | 2023-12-31 | 42.44M | +21.6% |
| FY2022 | 2022-12-31 | 34.89M | +87.9% |
| FY2021 | 2021-12-31 | 18.57M | — |
Research & Development vs competitors
How DH compares with its peers on the latest reported figures
- DH's LTM Mar 2026 research & development of $31.97M is the 6th highest of the 10 companies compared; the peer median is $35.89M.
- Its year-over-year change of -10.4% is the 7th highest of 9, against a peer median of +6.3%.
- Research & development amounts to 13.4% of revenue for DH, versus a peer median of 11.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $151.01M | +44.8% | +53.7% | — | |
| LTM Mar 2026 | $126.01M | -0.7% | +67.6% | — | |
| LTM Mar 2026 | $66.19M | -62.3% | -19.9% | 171.1% | |
| LTM Mar 2026 | $39.88M | +24.6% | +1.7% | 11.5% | |
| LTM Mar 2026 | $35.89M | +5.3% | -1.7% | 44.2% | |
| LTM Mar 2026 | $31.97M | -10.4% | -0.1% | 13.4% | |
| LTM Mar 2026 | $12.5M | +7.2% | -3.9% | 9.1% | |
| LTM Feb 2026 | $9.34M | +29.5% | +29.0% | 11.6% | |
| LTM Mar 2026 | $4 | -100.0% | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding DH) | $35.89M | +6.3% | +1.7% | 11.5% | |
Competitors are the stored peer set for DH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 166.15M | 222.65M | 251.42M | 252.2M | 241.52M |
| Cost of Revenue | 40.69M | 42.63M | 47.48M | 54.73M | 58.25M |
| Gross Profit | 125.47M | 180.03M | 203.93M | 197.47M | 183.28M |
| Gross Margin | 75.5% | 80.9% | 81.1% | 78.3% | 75.9% |
| Research & Development | 18.57M | 34.89M | 42.44M | 36.52M | 34.78M |
| Selling, General & Admin | 89.25M | 141.15M | 153.4M | 133.07M | 133.26M |
| Operating Expenses | 152.78M | 224.07M | 533.73M | 908.29M | 203.86M |
| Depreciation & Amortization | 59.95M | 56.9M | 51.75M | 51.67M | 35.82M |
| EBITDA | 23.08M | 26.23M | (241.23M) | (567.24M) | (162.15M) |
| EBITDA Margin | 13.9% | 11.8% | -95.9% | -224.9% | -67.1% |
| Operating Income | (27.32M) | (44.04M) | (329.8M) | (710.82M) | (20.58M) |
| Operating Margin | -16.4% | -19.8% | -131.2% | -281.8% | -8.5% |
| Interest Income | 29K | 2.79M | 13.64M | 14.59M | 6.95M |
| Interest Expense | 25.9M | 11.2M | 15.2M | 14.84M | 11.29M |
| Other Income / Expenses | (35.45M) | 2.17M | 21.62M | 77.08M | (188.67M) |
| Income Before Tax | (62.77M) | (41.88M) | (308.18M) | (633.75M) | (209.26M) |
| Pre-Tax Margin | -37.8% | -18.8% | -122.6% | -251.3% | -86.6% |
| Income Tax Expense | (443K) | (17.7M) | (18.55M) | (42.3M) | (9.96M) |
| Net Income | (51.91M) | (7.22M) | (202.39M) | (413.12M) | (138.93M) |
| Net Margin | -31.2% | -3.2% | -80.5% | -163.8% | -57.5% |
| EPS (Basic) | (0.19) | (0.07) | (1.79) | (3.54) | (1.30) |
| EPS (Diluted) | (0.19) | (0.07) | (1.79) | (3.54) | (1.30) |
| Weighted Avg Shares | 97.03M | 101.11M | 112.76M | 116.64M | 106.65M |
| Weighted Avg Shares (Diluted) | 97.03M | 101.11M | 112.76M | 116.64M | 106.65M |
Definitive Healthcare Corp.
NASDAQ:DH
Intrinsic Alpha fair value
Locked
Current Price
$1.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.